{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:55:53Z","timestamp":1790621753323,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T00:00:00Z","timestamp":1470700800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s00259-016-3475-5","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T04:48:32Z","timestamp":1470718112000},"page":"63-70","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET\/CT in anal canal cancer"],"prefix":"10.1007","volume":"44","author":[{"given":"Mathieu","family":"Gauth\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Richard-Molard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Fayard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Alberini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wulfran","family":"Cacheux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Li\u00e8vre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,9]]},"reference":[{"key":"3475_CR1","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER Stat Fact Sheets: Anal Cancer. Bethesda, MD: National Cancer Institute. 2016. http:\/\/seer.cancer.gov\/statfacts\/html\/anus.html . Accessed 4 Aug 2016"},{"key":"3475_CR2","first-page":"165","volume-title":"AJCC cancer staging manual","author":"S Edge","year":"2010","unstructured":"Edge S, Byrd D, Compton CC, Fritz A, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. p. 165\u201373.","edition":"7"},{"key":"3475_CR3","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","volume":"299","author":"JA Ajani","year":"2008","unstructured":"Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson 3rd AB, Thomas Jr CR, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299:1914\u201321.","journal-title":"JAMA"},{"key":"3475_CR4","doi-asserted-by":"crossref","unstructured":"Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson 3rd AB, Thomas Jr CR, et al. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer. 2010;116:4007\u201313.","DOI":"10.1002\/cncr.25188"},{"key":"3475_CR5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2967\/jnumed.112.109470","volume":"54","author":"JG Bazan","year":"2013","unstructured":"Bazan JG, Koong AC, Kapp DS, Quon A, Graves EE, Loo BW, et al. Metabolic tumor volume predicts disease progression and survival in patients with squamous cell carcinoma of the anal canal. J Nucl Med. 2013;54:27\u201332.","journal-title":"J Nucl Med"},{"key":"3475_CR6","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ijrobp.2007.04.036","volume":"69","author":"P Lee","year":"2007","unstructured":"Lee P, Weerasuriya DK, Lavori PW, Quon A, Hara W, Maxim PG, et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys. 2007;69:328\u201333.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3475_CR7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2967\/jnumed.111.099531","volume":"53","author":"EH Dibble","year":"2012","unstructured":"Dibble EH, Alvarez ACL, Truong M-T, Mercier G, Cook EF, Subramaniam RM. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J Nucl Med. 2012;53:709\u201315.","journal-title":"J Nucl Med"},{"key":"3475_CR8","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.ijrobp.2009.06.049","volume":"77","author":"D Schellenberg","year":"2010","unstructured":"Schellenberg D, Quon A, Minn AY, Graves EE, Kunz P, Ford JM, et al. 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 2010;77:1420\u20135.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3475_CR9","unstructured":"Benson AB 3rd, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS et al. Anal carcinoma. In: NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network.\u00a02016. http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp . Accessed 4 Aug 2016."},{"key":"3475_CR10","unstructured":"Deutsch E, Brunet R, Peiffert D, Salmon R, Siproudhis L, Touboul E. Cancer du canal anal. In: Th\u00e9saurus National de Canc\u00e9rologie Digestive (TNCD). Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de Gastro-Ent\u00e9rologie. 2010. http:\/\/www.tncd.org\/ . Accessed 4 Aug 2016."},{"key":"3475_CR11","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ijrobp.2006.01.009","volume":"65","author":"SE Cotter","year":"2006","unstructured":"Cotter SE, Grigsby PW, Siegel BA, Dehdashti F, Malyapa RS, Fleshman JW, et al. FDG-PET\/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys. 2006;65:720\u20135.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3475_CR12","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/bjc.2011.274","volume":"105","author":"FL Day","year":"2011","unstructured":"Day FL, Link E, Ngan S, Leong T, Moodie K, Lynch C, et al. FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy. Br J Cancer. 2011;105:498\u2013504.","journal-title":"Br J Cancer"},{"key":"3475_CR13","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.ijrobp.2011.02.010","volume":"82","author":"C Ortholan","year":"2012","unstructured":"Ortholan C, Resbeut M, Hannoun-Levi J-M, Teissier E, Gerard J-P, Ronchin P, et al. Anal canal cancer: management of inguinal nodes and benefit of prophylactic inguinal irradiation (CORS-03 Study). Int J Radiat Oncol Biol Phys. 2012;82:1988\u201395.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3475_CR14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ijrobp.2011.07.007","volume":"83","author":"JM Tomaszewski","year":"2012","unstructured":"Tomaszewski JM, Link E, Leong T, Heriot A, Vazquez M, Chander S, et al. Twenty-five-year experience with radical chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2012;83:552\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3475_CR15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijrobp.2013.03.008","volume":"87","author":"T Zilli","year":"2013","unstructured":"Zilli T, Betz M, Bieri S, Ris F, Roche B, Roth AD, et al. Elective inguinal node irradiation in early-stage T2N0 anal cancer: prognostic impact on locoregional control. Int J Radiat Oncol. 2013;87:60\u20136.","journal-title":"Int J Radiat Oncol"},{"key":"3475_CR16","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","volume":"30","author":"LL Gunderson","year":"2012","unstructured":"Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB, et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin. J Clin Oncol. 2012;30:4344\u201351.","journal-title":"J Clin Oncol"},{"key":"3475_CR17","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","volume":"14","author":"M Flam","year":"1996","unstructured":"Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527\u201339.","journal-title":"J Clin Oncol"},{"key":"3475_CR18","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","volume":"14","author":"RD James","year":"2013","unstructured":"James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2\u2009\u00d7\u20092 factorial trial. Lancet Oncol. 2013;14:516\u201324.","journal-title":"Lancet Oncol"},{"key":"3475_CR19","doi-asserted-by":"crossref","unstructured":"Peiffert D, Giovannini M, Ducreux M, Michel P, Fran\u00e7ois E, Lemanski C, et al. High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: final results of a phase II study. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2001;12:397\u2013404.","DOI":"10.1023\/A:1011107105538"},{"key":"3475_CR20","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","volume":"30","author":"D Peiffert","year":"2012","unstructured":"Peiffert D, Tournier-Rangeard L, G\u00e9rard J-P, Lemanski C, Fran\u00e7ois E, Giovannini M, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol. 2012;30:1941\u20138.","journal-title":"J Clin Oncol"},{"key":"3475_CR21","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00261-012-9958-3","volume":"38","author":"SS Saboo","year":"2012","unstructured":"Saboo SS, Zukotynski K, Shinagare AB, Krajewski KM, Ramaiya N. Anal carcinoma: FDG PET\/CT in staging, response evaluation, and follow-up. Abdom Imaging. 2012;38:728\u201335.","journal-title":"Abdom Imaging"},{"key":"3475_CR22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00384-010-1080-9","volume":"26","author":"L Vercellino","year":"2010","unstructured":"Vercellino L, Montravers F, de Parades V, Huchet V, Kerrou K, Bauer P, et al. Impact of FDG PET\/CT in the staging and the follow-up of anal carcinoma. Int J Colorectal Dis. 2010;26:201\u201310.","journal-title":"Int J Colorectal Dis"},{"key":"3475_CR23","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijrobp.2007.09.005","volume":"71","author":"JK Schwarz","year":"2008","unstructured":"Schwarz JK, Siegel BA, Dehdashti F, Myerson RJ, Fleshman JW, Grigsby PW. Tumor response and survival predicted by post-therapy FDG-PET\/CT in anal cancer. Int J Radiat Oncol Biol Phys. 2008;71:180\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3475_CR24","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.radonc.2010.02.019","volume":"95","author":"EA Kidd","year":"2010","unstructured":"Kidd EA, Dehdashti F, Siegel BA, Grigsby PW. Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis. Radiother Oncol. 2010;95:288\u201391.","journal-title":"Radiother Oncol"},{"key":"3475_CR25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijrobp.2011.10.048","volume":"84","author":"M Mistrangelo","year":"2012","unstructured":"Mistrangelo M, Pelosi E, Bell\u00f2 M, Ricardi U, Milanesi E, Cassoni P, et al. Role of positron emission tomography-computed tomography in the management of anal cancer. Int J Radiat Oncol. 2012;84:66\u201372.","journal-title":"Int J Radiat Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-016-3475-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-016-3475-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-016-3475-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T20:14:39Z","timestamp":1498335279000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-016-3475-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,9]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["3475"],"URL":"https:\/\/doi.org\/10.1007\/s00259-016-3475-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,9]]}}}